Faruqi & Faruqi Investigates Inovio Investor Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2026
0mins
Should l Buy INO?
Source: PRnewswire
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Inovio Pharmaceuticals for potential claims related to investor losses incurred between October 10, 2023, and December 26, 2025, highlighting the firm's commitment to protecting investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly via phone at 877-247-4292 or 212-983-9330, aiming to assist them in understanding their legal options.
- Class Action Reminder: The firm reminds investors that April 7, 2026, is the deadline to seek lead plaintiff status in the federal securities class action filed against Inovio, underscoring the importance of timely action for affected parties.
- Potential Claim Risks: As the investigation progresses, the potential claim risks facing Inovio could impact the company's reputation and future stock price, reflecting market concerns regarding the company's compliance and governance practices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.630
Low
3.00
Averages
7.33
High
13.00
Current: 1.630
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovio Pharmaceuticals Shareholder Class Action Notice
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Inovio Pharmaceuticals, encouraging those who purchased INO shares between October 10, 2023, and December 26, 2025, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- Allegations: The complaint alleges that during the class period, Inovio made materially false and misleading statements, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which may delay the submission of its lead product candidate INO-3107 to the FDA until the second half of 2024.
- Regulatory Uncertainty: Inovio lacked sufficient information to justify INO-3107's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects, which could result in significant losses for investors.
- Participation Deadline: The deadline for shareholders to register for the class action is April 7, 2026, and those who do not register may miss the opportunity for claims, thus it is advised to act promptly to protect their rights.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Notification
- Class Action Initiation: Levi & Korsinsky LLP has notified investors in Inovio Pharmaceuticals of a class action lawsuit due to alleged securities fraud, covering the period from October 10, 2023, to December 26, 2025, aimed at recovering losses for affected investors.
- Allegation Details: The complaint alleges that defendants concealed deficiencies in the manufacturing of Inovio's CELLECTRA device, which may delay the submission of its lead product candidate, INO-3107, to the FDA until the second half of 2024, and lacked sufficient information to justify its eligibility for accelerated approval, impacting its market prospects.
- Investor Rights: Affected investors have until April 7, 2026, to request to be appointed as lead plaintiff, with participation in any recovery requiring no out-of-pocket costs, ensuring investor rights are protected.
- Legal Team Strength: Levi & Korsinsky boasts 20 years of experience in securities litigation, having secured hundreds of millions for shareholders, and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years, showcasing its expertise in complex securities cases.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Inovio Pharmaceuticals and certain executives in the Eastern District of Pennsylvania, representing investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, seeking damages for violations of federal securities laws.
- FDA Approval Delay: On August 8, 2024, Inovio disclosed in its financial results that it expected to submit the INO-3107 Biologics License Application to the FDA by mid-2025, a full year later than initially projected, resulting in a 3.1% drop in stock price the following day.
- Regulatory Uncertainty: On December 29, 2025, Inovio announced that the FDA accepted the INO-3107 application for standard review rather than accelerated approval, causing a significant stock price decline of 24.45%, closing at $1.73.
- False Statements Allegations: The lawsuit alleges that Inovio executives made materially false and misleading statements throughout the class period, failing to disclose manufacturing deficiencies in the CELLECTRA device, which misled investors regarding the company's prospects.
See More
Inovio Pharmaceuticals Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong track record and expertise in the field.
- Investor Guidance: Investors are advised to carefully select their legal counsel, with Rosen Law Firm emphasizing its specialization in securities class actions and cautioning against choosing inexperienced intermediaries to ensure optimal legal representation.
See More
Class Action Lawsuit Announced Against Inovio Pharmaceuticals
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Inovio Pharmaceuticals for securities purchases made between October 10, 2023, and December 26, 2025, potentially impacting investors' rights to compensation.
- Legal Procedure Details: Investors can apply to be lead plaintiffs by April 7, 2026, representing other members in the litigation, indicating that the legal process will continue and may affect Inovio's market performance.
- False Statement Allegations: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, which may have led to investor losses.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Inovio Pharmaceuticals and certain officers, seeking damages for investors who acquired Inovio securities between October 10, 2023, and December 26, 2025, reflecting strong investor concerns over potential fraud.
- Allegations of False Statements: The complaint alleges that Inovio made materially false and misleading statements during the class period, particularly regarding deficiencies in the manufacturing of its CELLECTRA device and the regulatory prospects of INO-3107, severely undermining investor confidence in the company’s future.
- Uncertain Regulatory Outlook: The lawsuit indicates that Inovio is unlikely to submit the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024, suggesting that the commercial prospects of its products have been significantly overstated, which could negatively impact stock prices and investor sentiment.
- Investor Rights Protection: Investors have until April 7, 2026, to request to be appointed as lead plaintiff, with the law firm offering legal support on a contingency fee basis, demonstrating a strong commitment to protecting investor rights and ensuring corporate accountability.
See More
Inovio Pharmaceuticals Shareholder Class Action Notice
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Inovio Pharmaceuticals, encouraging those who purchased INO shares between October 10, 2023, and December 26, 2025, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- Allegations: The complaint alleges that during the class period, Inovio made materially false and misleading statements, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which may delay the submission of its lead product candidate INO-3107 to the FDA until the second half of 2024.
- Regulatory Uncertainty: Inovio lacked sufficient information to justify INO-3107's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects, which could result in significant losses for investors.
- Participation Deadline: The deadline for shareholders to register for the class action is April 7, 2026, and those who do not register may miss the opportunity for claims, thus it is advised to act promptly to protect their rights.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Notification
- Class Action Initiation: Levi & Korsinsky LLP has notified investors in Inovio Pharmaceuticals of a class action lawsuit due to alleged securities fraud, covering the period from October 10, 2023, to December 26, 2025, aimed at recovering losses for affected investors.
- Allegation Details: The complaint alleges that defendants concealed deficiencies in the manufacturing of Inovio's CELLECTRA device, which may delay the submission of its lead product candidate, INO-3107, to the FDA until the second half of 2024, and lacked sufficient information to justify its eligibility for accelerated approval, impacting its market prospects.
- Investor Rights: Affected investors have until April 7, 2026, to request to be appointed as lead plaintiff, with participation in any recovery requiring no out-of-pocket costs, ensuring investor rights are protected.
- Legal Team Strength: Levi & Korsinsky boasts 20 years of experience in securities litigation, having secured hundreds of millions for shareholders, and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years, showcasing its expertise in complex securities cases.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Inovio Pharmaceuticals and certain executives in the Eastern District of Pennsylvania, representing investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, seeking damages for violations of federal securities laws.
- FDA Approval Delay: On August 8, 2024, Inovio disclosed in its financial results that it expected to submit the INO-3107 Biologics License Application to the FDA by mid-2025, a full year later than initially projected, resulting in a 3.1% drop in stock price the following day.
- Regulatory Uncertainty: On December 29, 2025, Inovio announced that the FDA accepted the INO-3107 application for standard review rather than accelerated approval, causing a significant stock price decline of 24.45%, closing at $1.73.
- False Statements Allegations: The lawsuit alleges that Inovio executives made materially false and misleading statements throughout the class period, failing to disclose manufacturing deficiencies in the CELLECTRA device, which misled investors regarding the company's prospects.
See More
Inovio Pharmaceuticals Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong track record and expertise in the field.
- Investor Guidance: Investors are advised to carefully select their legal counsel, with Rosen Law Firm emphasizing its specialization in securities class actions and cautioning against choosing inexperienced intermediaries to ensure optimal legal representation.
See More
Class Action Lawsuit Announced Against Inovio Pharmaceuticals
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Inovio Pharmaceuticals for securities purchases made between October 10, 2023, and December 26, 2025, potentially impacting investors' rights to compensation.
- Legal Procedure Details: Investors can apply to be lead plaintiffs by April 7, 2026, representing other members in the litigation, indicating that the legal process will continue and may affect Inovio's market performance.
- False Statement Allegations: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, which may have led to investor losses.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Inovio Pharmaceuticals and certain officers, seeking damages for investors who acquired Inovio securities between October 10, 2023, and December 26, 2025, reflecting strong investor concerns over potential fraud.
- Allegations of False Statements: The complaint alleges that Inovio made materially false and misleading statements during the class period, particularly regarding deficiencies in the manufacturing of its CELLECTRA device and the regulatory prospects of INO-3107, severely undermining investor confidence in the company’s future.
- Uncertain Regulatory Outlook: The lawsuit indicates that Inovio is unlikely to submit the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024, suggesting that the commercial prospects of its products have been significantly overstated, which could negatively impact stock prices and investor sentiment.
- Investor Rights Protection: Investors have until April 7, 2026, to request to be appointed as lead plaintiff, with the law firm offering legal support on a contingency fee basis, demonstrating a strong commitment to protecting investor rights and ensuring corporate accountability.
See More
